Genmab Reports New Epcoritamab Data, 93% Response Rate in DLBCL Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Newsfilter
- Clinical Trial Results: In the EPCORE NHL-2 trial, the combination of Epcoritamab with R-mini-CHOP achieved an overall response rate (ORR) of 93% in newly diagnosed DLBCL patients, demonstrating the therapy's efficacy and tolerability in elderly populations.
- Long-term Survival Rates: Results from the EPCORE DLBCL-3 trial indicated a three-year overall survival rate of 96% for elderly patients with newly diagnosed DLBCL treated with Epcoritamab monotherapy, highlighting its potential for long-term efficacy in high-risk patients.
- Treatment Safety: In the EPCORE NHL-2 trial, 32% of patients experienced grade 3 or higher infections; however, the safety profile of Epcoritamab remained consistent with previous studies, with no new serious adverse events reported, indicating good tolerability.
- Market Outlook: The positive clinical data for Epcoritamab supports its role as a core therapy for DLBCL and FL, with Genmab planning to advance its use across various B-cell malignancies, which is expected to drive future growth for the company.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 33.100
Low
26.00
Averages
38.50
High
48.00
Current: 33.100
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
